Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Larynx | Lip, Oral Cavity and Pharynx
What is the purpose of this trial?
This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.
- Trial withYale Cancer Center
- Start Date04/02/2017
- End Date12/29/2019
- Last Updated06/18/2020
- Study HIC#1608018260